Recombinant Mouse IL-2 R alpha / CD25 Protein, His Tag, 100 µg

Background
Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

Source
Recombinant Mouse IL-2 R alpha, His Tag (ILA-M52H9) is expressed from human 293 cells (HEK293). It contains AA Glu 22 - Lys 236 (Accession # P01590-1).
Predicted N-terminus: Glu 22

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.6 kDa. The protein migrates as 40-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Dynamic indicators of acute respiratory diseases treatment in children after correction"
Horlenko, Pikina, Prylypko et al
Wiad Lek (2024) 77 (3), 543-550
(2)  "The Impact of Tumor Hypoxia Modulation on sIL-2R Levels in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients Undergoing Chemotherapy: A Randomized Clinical Trial"
Rizky, Tandarto, Pangarsa et al
Asian Pac J Cancer Prev (2024) 25 (4), 1315-1324
(3)  "Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)"
Mounika, Mungase, Verma et al
Inflammation (2024)
Showing 1-3 of 1709 papers.